Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Evaluate the Safety and Efficacy of HL-1186 Tablet for Postoperative Analgesia in Orthopedic Surgery

This clinical trial is a multiple-center, randomized, double-blind, placebo- and active-controlled parallel-group Phase II/III clinical trial, to evaluate the efficacy and safety of HL-1186 Tablets for Postoperative Analgesia in Orthopedic Surgery.

Participants needed: 330
Trial details
Phase: Phase 2, Phase 3Age: 18-75Biological sex: AllType: InterventionalSponsor: Shanghai Huilun Pharmaceutical Co., Ltd.Updated: Jul 13, 2026Locations: 1
Eligibility criteria

18 years old ≤ age ≤ 75 years old, gender is not limited. [+4]

Previous surgery on the same site that may affect pain perception at the surgica... [+10]

Status: Not yet recruiting

A Phase III Clinical Study of H077 Sustained-Release Tablets Compared With Silodosin Capsules in the Treatment of Benign Prostatic Hyperplasia

This is a randomized, double-blind, controlled, non-inferiority multicenter Phase III clinical study to evaluate the efficacy and safety of H077 sustained-release tablets versus silodosin capsules in treating benign prostatic hyperplasia.

Participants needed: 728
Trial details
Phase: Phase 3Age: 50-75Biological sex: MaleType: InterventionalSponsor: Shanghai Huilun Pharmaceutical Co., Ltd.Updated: Aug 28, 2025Locations: 66
Eligibility criteria

Male, aged 50 to 75 years old, inclusive of both endpoints; [+7]

Those who are allergic to any component of α/β-adrenergic receptor blockers or t... [+17]

Status: Not yet recruiting

A Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Inhaled H057 in the Treatment of Acute Exacerbations of Bronchiectasis

This is a multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of inhaled H057 in the treatment of acute exacerbations of bronchiectasis.

Participants needed: 180
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Shanghai Huilun Pharmaceutical Co., Ltd.Updated: May 9, 2025Locations: 19
Eligibility criteria

Age ≥18 years, regardless of gender; [+4]

Patients with bronchiectasis caused by cystic fibrosis, as determined by the inv... [+13]